Breast carcinoma: A report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease

被引:0
|
作者
Wigler, Nely [1 ]
Shina, Sima [1 ]
Kaplan, Ofer [1 ]
Luboshits, Galia [1 ]
Chaitchik, Samario [1 ]
Keydar, Iafa [1 ]
Ben-Baruch, Adit [1 ]
机构
[1] Dept. of Cell Res. and Immunology, Faculty of Life Sciences, Tel Aviv University, Ramat Aviv 69978, Israel
来源
Israel Medical Association Journal | 2002年 / 4卷 / 11 SUPPL.期
关键词
Diseases; -; Research; Tumors;
D O I
暂无
中图分类号
学科分类号
摘要
Background: High incidence and intensity of RANTES (CC chemokine) expression were noted in advanced breast carcinoma. Objective: To present two cases of breast carcinoma patients in whom RANTES expression was analyzed in parallel to disease progression. Results: Although no evidence of malignancy was detected in the axillary lymph nodes of the two patients, their disease progressed. The expression of RANTES in both patients was positive at diagnosis and predicted the clinical course. Conclusions: These results, combined with our previous findings on the correlation between RANTES expression and advanced breast carcinoma, suggest that the assessment of RANTES expression may be useful for the identification of patients with apparently poor prognosis who may benefit from aggressive treatment. The above results call for large-scale studies by numerous research groups to determine the prognostic value of RANTES expression.
引用
收藏
页码:940 / 943
相关论文
共 50 条
  • [1] Breast carcinoma: A report on the potential usage of the CC chemokine RANTES as a marker for a progressive disease
    Wigler, N
    Shina, S
    Kaplan, O
    Luboshits, G
    Chaitchik, S
    Keydar, I
    Ben-Baruch, A
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (11): : 940 - 943
  • [2] The CC chemokine RANTES as a potential contributor to breast cancer progression
    E Azenshtein
    G Luboshits
    S Shina
    E Neumark
    N Vigler
    S Chaitchik
    I Keydar
    A Ben-Baruch
    Breast Cancer Research, 3 (Suppl 1)
  • [3] The CC chemokine RANTES in breast carcinoma progression: Regulation of expression and potential mechanisms of promalignant activity
    Azenshtein, E
    Luboshits, G
    Shina, S
    Neumark, E
    Shahbazian, D
    Weil, M
    Wigler, N
    Keydar, I
    Ben-Baruch, A
    CANCER RESEARCH, 2002, 62 (04) : 1093 - 1102
  • [4] Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma
    Luboshits, G
    Shina, S
    Kaplan, O
    Engelberg, S
    Nass, D
    Lifshitz-Mercer, B
    Chaitchik, S
    Keydar, I
    Ben-Baruch, A
    CANCER RESEARCH, 1999, 59 (18) : 4681 - 4687
  • [5] A novel potential prognostic marker for breast carcinoma.
    Yousef, GM
    Kyriakopoulou, L
    Scorilas, A
    Ponzone, R
    Giai, M
    Sismondi, P
    Diamandis, EP
    Rendel, L
    Diamandis, M
    CLINICAL CHEMISTRY, 2001, 47 (06) : A130 - A130
  • [6] GATA3 as a potential marker for breast carcinoma
    Kjaer, Dorte
    Brugmann, Anja
    Nielsen, Soren
    Jensen, Vibeke
    APMIS, 2014, 122 : 13 - 13
  • [7] The Carcinoembryonic Antigen as a Potential Prognostic Marker for Neuroendocrine Carcinoma of the Breast
    Su, Chen-Hsien
    Chang, Han
    Chen, Chih-Jung
    Liu, Liang-Chih
    Wang, Hwei-Chung
    Lane, Hsien-Yuan
    Bau, Da-Tian
    ANTICANCER RESEARCH, 2012, 32 (01) : 183 - 188
  • [8] Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression
    Xiao, LH
    Rudolph, DL
    Owen, SM
    Spira, TJ
    Lal, RB
    AIDS, 1998, 12 (13) : F137 - F143
  • [9] Rosai-Dorfman disease of the breast: A potential marker of systemic disease
    Goldbach, Alyssa R.
    Hava, Sana
    Caroline, Dina
    Zhao, Xiaofeng
    Bains, Ashish
    Pascarella, Suzanne
    BREAST JOURNAL, 2019, 25 (01): : 134 - 137
  • [10] Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus
    Yanli Zeng
    Qiaoduan Lin
    Liang Yu
    Xuelian Wang
    Yiqiang Lin
    Yan Zhang
    Shuidi Yan
    Xinxin Lu
    Yijing Li
    Weibin Li
    Yun Xiao
    BMC Immunology, 22